



## MARC COUCKE APPOINTED CHAIRMAN OF MITHRA'S BOARD OF DIRECTORS

- Mithra Pharmaceuticals announced today the appointment of Marc Coucke as chairman of the Board of Directors.
- Other changes also occurred in the Board of Directors of Mithra Pharmaceuticals.
- Koen Hoffman, CEO of Value Square and former CEO of KBC Securities, was appointed independent director and will become chairman of the audit committee of Mithra.
- Freya Loncin, General Counsel Alychlo, was appointed new non-executive director.
- Professor Jean-Michel Foidart, co-founder of Mithra and current co-chairman of the Scientific Committee of Mithra Pharmaceuticals, was appointed non-executive director.

Liège, Belgium, 26 August 2016 – During the last board meeting, the Board of Directors of Mithra unanimously appointed Marc Coucke as Chairman.

**Marc Coucke, Chairman of the Board of Directors of Mithra Pharmaceuticals :** *“I thank the directors of Mithra for their trust. With my investment company Alychlo, I invested in several companies, mainly in Belgium. Today, I decided to play a more active role in one of these companies and became chairman of the Board of Directors of Mithra. Mithra is a company with a significant potential. The financial strategy and the choice of the right partners are decisive aspects for the creation of value for the shareholders. I look forward to sitting as chairman of an active Board of Directors which, in collaboration with its CEO François Fornieri and its management team, will defend at most the interests of shareholders.”*

### Other changes for the Board of Directors of Mithra Pharmaceuticals

After the resignation of Barbara De Saedeleer and Marc Foidart and after the death of Jean Sequaris on the 8<sup>th</sup> July, three new members have been appointed in the Board of Directors of Mithra :

- Koen Hoffman, CEO of Value Square and former CEO of KBC Securities, as new independent director and chairman of the audit committee of Mithra.
- Freya Loncin, General Counsel Alychlo, as new non-executive director.
- Jean-Michel Foidart, co-founder of Mithra and current co-chairman of the scientific committee of Mithra Pharmaceuticals, as non-executive director.

**François Fornieri, CEO of Mithra Pharmaceuticals:** *“All the members of the Board of Directors join me to congratulate Barbara De Saedeleer and Marc Foidart for all the accomplished work and all the support they brought to Mithra from the very next day after its IPO up to now. Mithra is also very sad about the death of Jean Sequaris who, even with his health problems, always attended and actively participated to the meetings of the Board of Directors of Mithra.”*

**Marc Coucke, Chairman of the Board of Directors of Mithra Pharmaceuticals:** *“The profile of the new directors perfectly correspond to the key skills required in the Board of Directors of Mithra. The financial management of Koen Hoffman, the corporate governance of Freya Loncin and the scientific expertise of Professor Jean-Michel Foidart were unanimously welcomed by the board.”*

## Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/logo/>

## For more information, please contact:

### Press

#### **Julie Dessart**

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

[press@mithra.com](mailto:press@mithra.com)

### Investor Relations

#### **François Fornieri, CEO**

+32 4 349 28 22

[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

## About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women’s Health. Mithra’s mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women’s health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women’s health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are*

*cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To subscribe to Mithra's newsletter, visit [investors.mithra.com](https://investors.mithra.com)